Neuro-oncology
Extended follow-up from the phase 3 INDIGO trial presented at ASCO 2026 provides further evidence that vorasidenib may offer durable disease control in patients with grade 2 glioma harboring IDH1/2 mutations, reinforcing earlier findings that led to its regulatory approvals. In the article below, we provide a details analysis of the latest INDIGO data and Dr Timothy Cloughesy's expert perspective on what the longer-term efficacy and safety findings could mean for the evolving treatment landscape in IDH-mutant glioma.
At ASCO 2026 several neuro-oncology presentations focused less on introducing entirely new paradigms and more on defining where existing and emerging therapies may best fit. Across brain metastases and glioma, phase 3 data addressed longstanding practical questions around radiation delivery, chemotherapy duration, and local therapies, while updated targeted therapy data in IDH-mutant glioma continued to mature. In this piece, Dr Rimas Lukas highlights four main abstracts from ASCO 2026, discussing their take-aways and considering their potential relevance for clinical practice.
Glioblastoma (GBM) places an enormous emotional and practical burden on both patients and caregivers. At AAN 2026, Dr Jigisha Thakkar et al. explored how cultural and ethnic differences influence preferences for communication and care delivery in neuro-oncology settings. In this Q&A, Dr Thakkar discusses the key takeaways from her study, and how these findings could help shape more individualized approaches to neuro-oncologic care.
At AAN 2026, Dr Jigisha Thakkar presented data challenging long-standing assumptions of continuous tumor growth and suggesting that some patients may benefit from more individualized surveillance and treatment strategies. In this Q&A, Dr Thakkar discusses how intermittent dormancy in IDH-mutant gliomas may influence clinical decision-making, from MRI surveillance intervals to the timing of therapeutic intervention.
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Among glial tumours of the central nervous system (CNS), one of the most devastating is the category of H3K27-altered midline gliomas because of their uniform and rapid mortality, high neurological symptom burden and predilection for paediatric, adolescent and ...
See who the oncology community selected as the rising stars of 2026!
We are delighted to announce Dr Rahat Ul Ain as a touchONCOLOGY Future Leader 2026, selected as a rising star poised to shape the future of CNS tumors, Hodgkin lymphoma and immunodeficiency-associated cancers.
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Dr Rimas Lukas highlights early-stage neuro-oncology research presented at ANA 2025. Key approaches targeting CNS tumours include immune checkpoint inhibition, patient-derived glioblastoma vaccines, focused ultrasound, and cGAS–STING pathway therapies. The session showcased innovative strategies aiming to harness immunity in the fight against these difficult-to-treat cancers.
At #ASCO25, key neuro-oncology presentations explored focused ultrasound to enhance drug delivery, the benefits of maximal surgical resection in IDH-mutant gliomas, and final CATNON data supporting adjuvant temozolomide. Other highlights included improved cognitive outcomes with stereotactic radiosurgery for brain metastases and early results from a novel gamma delta T cell therapy.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
“When a child lights up seeing you and runs from the other side of the room to hug you… I’m reminded of the long-lasting, positive impact we can have” Dr Andrada Țurcaș (Babes-Bolyai University Cluj-Napoca, Romania) is a radiation ...
In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital ...
The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1 Standard of care therapy, which includes a maximal ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
